Splanchnic Vasodilation in Cirrhosis

Epidemiology and Clinical Significance

The European Association for the Study of the Liver recommends that splanchnic vasodilation be recognized as a fundamental pathophysiological mechanism underlying the hyperdynamic circulatory syndrome in cirrhosis, which occurs in the vast majority of patients with decompensated cirrhosis and portal hypertension, with a prevalence of nearly universal in advanced cirrhosis 1, 2
Among cirrhotic patients, kidney dysfunction occurs in 20% of hospitalized patients and >50% of outpatients with decompensated cirrhosis, often precipitated by the hemodynamic consequences of splanchnic vasodilation 3
Nearly 60% of patients with compensated cirrhosis will develop ascites within a decade, which is a direct consequence of the splanchnic vasodilation-induced hemodynamic changes 4

The American Association for the Study of Liver Diseases notes that splanchnic vasodilation creates effective arterial underfilling rather than true hypovolemic shock, triggered by portal hypertension and leading to effective hypovolemia despite actual hypervolemia 4, 3
The vasodilation results from increased production of vasodilators and impaired responsiveness to vasoconstrictors, activating compensatory vasoconstrictor systems, leading to renal vasoconstriction and sodium/water retention 3, 1

Patients with advanced cirrhosis have increased susceptibility to shock due to reduced effective volaemia and cardiovascular dysfunction, with splanchnic vasodilation creating a baseline state of hemodynamic compromise 1
When bacterial infection occurs, the additional vasodilatory effects of bacterial products and cytokines worsen the existing splanchnic and systemic vasodilation, potentially leading to septic shock 3
Cirrhotic cardiomyopathy compounds the problem by preventing adequate cardiac output increases to compensate for the vasodilation, particularly in advanced stages 1

The presence of splanchnic vasodilation indicates high risk for complications, including hepatorenal syndrome, which develops as a direct consequence of splanchnic vasodilation-induced renal vasoconstriction 4, 5
The International Club of Ascites recommends that mean arterial pressure should be maintained >65 mmHg to ensure adequate perfusion pressure for splanchnic organs, as these patients have compromised autoregulation 6
Beta-blockers should be used with caution in patients with refractory ascites, as excessive reduction in cardiac output can worsen effective hypovolemia, according to the Asian Pacific Association for the Study of the Liver 7

Portal hypertension is the essential prerequisite for splanchnic vasodilation; elevated portal pressure directly induces arterial vasodilation in the splanchnic circulation. 8, 9
Splanchnic vasodilation in cirrhosis results from a triad of increased endogenous vasodilators (especially nitric oxide), reduced vascular responsiveness to vasoconstrictors, and chronic systemic inflammation driven by bacterial translocation from the gut. 10
Chronic inflammation caused by bacterial translocation is a primary driver of the vasodilatory state rather than a mere consequence. 10
Gut‑derived pathogen‑associated molecular patterns (PAMPs) and liver‑derived danger‑associated molecular patterns (DAMPs) activate immune cells, which release pro‑inflammatory cytokines, chemokines, and reactive oxygen/nitrogen species that further stimulate endothelial vasodilator production. 10
Alterations in the intestinal microbiome together with increased intestinal permeability facilitate bacterial translocation, perpetuating the inflammatory cascade. 10

The vasodilation creates “effective arterial underfilling”: despite overall hypervolemia, blood pools in the dilated splanchnic circulation, reducing the effective circulating volume. 9, 11

The perceived hypovolemia activates the renin‑angiotensin‑aldosterone system, the sympathetic nervous system, and arginine‑vasopressin secretion. 10, 9, 12
These compensatory mechanisms induce renal vasoconstriction and promote sodium/water retention, leading to ascites formation. 9, 11, 12
Neurohumoral activation secondary to effective arterial underfilling is identified as the central pathophysiological event linking portal hypertension to the major complications of decompensated cirrhosis. 11

Splanchnic vasodilation directly contributes to the development of hepatorenal syndrome by causing renal hypoperfusion. 8, 9
The vasodilated state increases susceptibility to shock, particularly when superimposed bacterial infection adds additional vasodilatory stress. 10
Cirrhotic cardiomyopathy compounds the problem by limiting the ability of the heart to increase output sufficiently to offset the splanchnic vasodilation. 10